Clinical Trials Browser

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06676449 2026-01-07

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

Phase 3 Recruiting

432 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT06869213 2025-10-02

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT06869226 2025-10-02

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Phase 2 Recruiting

283 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT05357846 2025-06-12

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Phase 3 Recruiting

422 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04278287 2024-12-13

Chemoradiotherapy in Unresectable Esophageal Cancer

Phase 1/2 Recruiting

105 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT06718205 2024-12-05

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting

112 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

917 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT06084897 2024-06-14

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Phase 2 Recruiting

120 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT05490719 2024-05-21

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Phase 2 Recruiting

39 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05281003 2023-07-13

HYPERION

Phase 2 Recruiting

128 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Hypoxia, Digestive System Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT05800054 2023-04-05

Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer

Phase NA Recruiting

210 enrolled

Gastrointestinal

Esophageal Neoplasms, Drug-Related Side Effects and Adverse Reactions

Clinical Trials

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

DG-03

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Chemoradiotherapy in Unresectable Esophageal Cancer

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

AB122 Platform Study

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

HYPERION

Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer